Chimeric antigen receptor specific for tumor cells

US10617720B2 · kind B2 · utility

Assignee

• Miltenyi Biotech, GmbH · DE

Inventors

• Dominik Eckardt · Moitzfeld, DE
• Andreas Bosio · Cologne, DE
• Olaf Hardt · Cologne, DE
• Andrzej Dzionek · Overath, DE
• Stefan Tomiuk · Neunburg vorm Wald, DE
• Jutta Kollet · Bonn, DE

Key dates

• Filing date: Oct 17, 2017
• Grant date: Apr 14, 2020
• Expiry date: May 12, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/40
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to ligand like a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for one or more antigens selected from the group consisting of CLA, CD142, CD73, CD49c, CD66c, CD104, CD318 and TSPAN8; cell populations expressing such CARs and the use of the cell populations for cancer therapy.